Product Image
InnoCirco vaccine
Components
- Recombinant PCV2d Protein
- IMS1313
Efficacy and effectiveness
- Prevention of systemic infection by Porcine Circovirus type 2 (PCV2)
- Provides high safety with no adverse effect
Usage and Capacity
- 1 injection of 2mL into a pig of 3 weeks or older
- Shake enough vaccine before use
InnoCirco
- Excellent vaccine for preventing Porcine Circovirus type 2 (PCV2) infection
- Safe and effective vaccine using PCV2d genotype-based virus-like particle antigen, a pioneering breakthrough
Product Overview
| Product Name | InnoCirco |
|---|---|
| Time for vaccination | 1 inoculation to pigs aged 3 weeks or older |
| Vaccination method | Injection once by Intramuscular injection with 1mL of vaccine |
| Efficacy and effectiveness | Prevention and relief of symptoms related to Porcine Circovirus type 2 (PCV2) |
Product Properties
- World's First PCV2d genetic-based recombinant Vaccine
- Long-lasting neutralizing antibody against PCV2 for 22 weeks (until shipment)
- Induces high potent neutralization antibodies against PCV2a, PCV2b, and PCV2d
- Contains IMS1313 (Seppic), a proven safe and effective adjuvant
Symptoms of Porcine Circovirus type 2 infection
- PCV2 infection is the primary cause of mortality by PMWS.
- Upon infection, PCV2 disseminates to systemic organs, manifesting clinical symptoms due to elevated viral titer in the bloodstream.
- PCV2-induced immunosuppression makes pigs susceptible to secondary infections resulting in increased mortality and retarded growth.
- Co-infection with Swine Mycoplasma leads to a significant surge in mortality.
Product Distinct Value
- Differential efficacy of InnoCirco vaccine in comparison to existing PCV2 vaccines has been identified
- Exceptional evaluation defense against PCV2d in SPF pigs demonstrates the effectiveness of InnoCirco Vaccine
- Superiority of neutralizing antibodies to PCV2 in serum has been verified
- Outstanding defense effectiveness confirmed in Porcine Circovirus Attack Vaccination Test
- Remarkable defense effectiveness of InnoCirco vaccine confirmed in challenge test with PCV2
- Identification of superior efficacy in clearance of PCV2 in target tissues
- InnoCirco Vaccine shows no detection of PCV2 antigen in serum and lymph nodes.
- Comparison test with existing commercial vaccines indicates no PCV2 detection in any tissues by immunohistochemical staining